1. Home
  2. SCLX vs SKYX Comparison

SCLX vs SKYX Comparison

Compare SCLX & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • SKYX
  • Stock Information
  • Founded
  • SCLX 2011
  • SKYX 2004
  • Country
  • SCLX United States
  • SKYX United States
  • Employees
  • SCLX N/A
  • SKYX N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • SKYX Building Products
  • Sector
  • SCLX Health Care
  • SKYX Consumer Discretionary
  • Exchange
  • SCLX Nasdaq
  • SKYX Nasdaq
  • Market Cap
  • SCLX 130.1M
  • SKYX 135.1M
  • IPO Year
  • SCLX N/A
  • SKYX 2022
  • Fundamental
  • Price
  • SCLX $0.61
  • SKYX $1.09
  • Analyst Decision
  • SCLX Strong Buy
  • SKYX Strong Buy
  • Analyst Count
  • SCLX 3
  • SKYX 3
  • Target Price
  • SCLX $11.33
  • SKYX $4.00
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • SKYX 392.5K
  • Earning Date
  • SCLX 11-26-2024
  • SKYX 11-12-2024
  • Dividend Yield
  • SCLX N/A
  • SKYX N/A
  • EPS Growth
  • SCLX N/A
  • SKYX N/A
  • EPS
  • SCLX N/A
  • SKYX N/A
  • Revenue
  • SCLX $50,833,000.00
  • SKYX $84,766,991.00
  • Revenue This Year
  • SCLX $32.77
  • SKYX $59.18
  • Revenue Next Year
  • SCLX $50.71
  • SKYX $42.08
  • P/E Ratio
  • SCLX N/A
  • SKYX N/A
  • Revenue Growth
  • SCLX 9.41
  • SKYX 131.47
  • 52 Week Low
  • SCLX $0.54
  • SKYX $0.72
  • 52 Week High
  • SCLX $2.63
  • SKYX $1.95
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 28.71
  • SKYX 40.23
  • Support Level
  • SCLX $0.73
  • SKYX $1.14
  • Resistance Level
  • SCLX $1.14
  • SKYX $1.44
  • Average True Range (ATR)
  • SCLX 0.11
  • SKYX 0.11
  • MACD
  • SCLX -0.04
  • SKYX -0.03
  • Stochastic Oscillator
  • SCLX 11.99
  • SKYX 4.92

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About SKYX SKYX Platforms Corp.

SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. The company's technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post and is capable of feeding electric power to an appliance. The Company generates its income from the United States.

Share on Social Networks: